GLP-1 and GLP-1/GIP RAs for obstructive sleep apnoea – What is their role?

Prof Brendon Yee

writer

Prof Brendon Yee

Respiratory and Sleep Medicine Physician; Woolcock Institute of Medical Research; Staff Specialist and Medical Director of Respiratory Failure Services, Royal Prince Alfred Hospital; Consultant, Rural Outreach Services

Claim CPD for this activity

Educational Activities (EA)

0.5 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

1 hours

These are activities that use your work data to ensure quality results.

EA
0.5 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 minutes

These are activities that require reflection on feedback about your work.

MO
1 minutes

These are activities that use your work data to ensure quality results.

Prof Brendon Yee

How new evidence will change how we assess and manage OSA

With obesity demonstrating mortality rates comparable to cigarette smoking, and obstructive sleep apnoea (OSA) potentially affecting up to one billion people worldwide, the intersection of these conditions demands innovative therapeutic approaches.

Recent advances in incretin-based therapies, particularly the GLP-1/GIP receptor agonist tirzepatide (Mounjaro), are revolutionising treatment for patients with concurrent obesity and OSA, offering clinically significant improvements that may challenge traditional CPAP-centric management strategies.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

References

  1. Benjafield AV, et al. Lancet Respir Med. 2019;7(8):687–98.
  2. Nieto FJ, et al. 2000;283(14):1829–36.
  3. Hedner J, et al. Eur Respir J. 2011;38(2):434–42.
  4. Peppard PE, et al. 2000;284(23):3015–21.
  5. Malhotra A, et al. Sleep Med. 2024;121:11.
  6. Davies MJ, et al. Diabetes Care. 2016;39(11):1972–80.
  7. Wilding JPH, et al. N Engl J Med. 2021;384(11):989–1002.
  8. Malhotra A, et al. N Engl J Med. 2024;391(15):1464–75.
  9. Azarbarzin A, et al. Eur Heart J. 2019;40(14):1149–57.
  10. Bratton DJ, et al. 2015;314(21):2280–93.
  11. Jastreboff AM, et al. N Engl J Med. 2025;392:958–71.
  12. Aronne LJ, et al. 2024;331(1):38–48.
  13. Jastreboff AM, et al. N Engl J Med. 2023;389:514–26.
  14. Gabryelska A, et al. J Clin Med. 2022;11(1):139.
  15. Javaheri S, et al. Chest. 2019;156(3):321–30.
  16. Abushamat LA, et al. Curr Cardiol Rep. 2024;26(7):739–47.
  17. Rubino F, et al. Nat Rev Endocrinol. 2020;16(12):715–16.
  18. Zhang Y, et al. Diabetes Obes Metab. 2023;25(11):2915–27.
  19. Loomba R, et al. N Engl J Med. 2023;389(4):336–49.
  20. Packer M, et al. N Engl J Med. 2023;389(12):1085–95.
  21. Siniukovich A, et al. Diabetol Metab Syndr. 2025;17:247.
  22. Bliddal H, et al. N Engl J Med. 2024;391(15):1464–75.
  23. Leggio L, et al. N Engl J Med. 2023;389(15):1399–409.
  24. Douros A, et al. Lancet Diabetes Endocrinol. 2024;12(5):327–36.
  25. Samms RJ et al. Trends in Endocrinology & Metabolism, 31 (6), 2020, 410-421.

Further your CPD learning

Based on this educational activity, complete these learning modules to gain additional CPD.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Debbie Rigby

A/Prof Debbie Rigby

Why Inhaler Device Design and Technique Matters

Dr Philip Tong

Dr Philip Tong

Facial Rashes Case Studies – Practical Guide to Assessment and Management

Dr Rupert Hinds

Dr Rupert Hinds

Abdominal Pain in Children – Practical Approach in GP

Prof Roger Chen

Prof Roger Chen

Practical Guide to Improving Control of T2D

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Prof Brendon Yee

writer

Prof Brendon Yee

Respiratory and Sleep Medicine Physician; Woolcock Institute of Medical Research; Staff Specialist and Medical Director of Respiratory Failure Services, Royal Prince Alfred Hospital; Consultant, Rural Outreach Services

Test your knowledge

Recent articles

Latest GP poll

In the last twelve months, how many adverse outcomes have you encountered arising from pharmacy prescribing?

None

0%

1-2

0%

Three or more

0%

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Upcoming Healthed Webcast

Tune in for "Facial rashes case studies - Practical guide to assessment and management" lecture

Tuesday 9th June, 7pm - 9pm AEST

Speaker

Dr Philip Tong

Consultant Dermatologist; Founder, DermScreen, Dermatology Junction; Visiting Medical Officer, St Vincent’s Hospital Sydney

What does it mean when a facial red rash does not respond to topical steroids and gets worse with the treatment? Dermatologist Dr Philip Tong presents a series of cases with this scenario.